Entry / Fusion Inhibitors (EI)

Safety and Efficacy of Maraviroc, a CCR5 Antagonist, for the Treatment of Treatment-experienced Patients Infected with Dual/Mixed-tropic HIV   - 8/18/06

A Phase II Study of the Safety and Efficacy of the CCR5 Antagonist Vicriviroc - 8/18/06

New Insights on Use by AIDS Patients of Pfizer’s Experimental CCR5 Antagonist Maraviroc   - 8/15/06